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generic revolution is still ahead and the drug market as a whole
will be deeply affected by an increasing number of generic drugs.
Public policy should take into account this evolution, in order to
maintain the industry capacity to innovate.
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ECONOMIC STUDIES USED BY DECISION MAKERS?
Fattore G, Torbica A
Bocconi University, Milan, Italy
OBJECTIVES: The number of economic evaluation studies has
grown extensively in recent years. However, a limited number of
studies investigated its impact on decision making; the gap is par-
ticularly evident in Italy where there are no such studies avail-
able. Objective of the research is to evaluate impact of economic
evaluation analysis on decision making in the Italian health care
system. The prospective taken is that of professionals operating
within the system. The aim is to investigate whether there are
evident differences in attitudes among professionals who conduct
different types of activities. METHODS: A 12 item based ques-
tionnaire was sent to 374 health care professionals who had
undergone some form of health economics training. The sample
was taken from a list of participants of a major health care man-
agement program at Bocconi School of Management in the last
10 years. RESULTS: Response rate was 35%. All respondents
stated that basics of economic evaluation analysis must be part
of the overall knowledge of health care professionals. Grade of
usefulness of these arguments in professional activities was rated
3.84 (scale 1–5). Respondents considered that economic evalua-
tion is more largely used in making managerial types of decisions
rather than clinical ones (mean 2.94 vs. 2.73). Decisions taken
according to short-term perspectives are considered the major
barrier in the use of economic evaluation studies, particularly 
by managers (71%). More training in health economics was 
indicated as the most relevant facilitating factor for a wider use
of studies, by both clinicians and managers (64%). Majority of
respondents (80%) considered that the maximum beneﬁts of eco-
nomic evaluation are taken from its use at the organizational
level. CONCLUSIONS: Although economic evaluation has a
rather modest impact on decision making in Italian health care,
there are some encouraging signs that could lead to its wider and
more effective use.
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OBJECTIVES: In Korea, even non-prescription drugs have been
on the list of reimbursable drugs, but recent suggestions are that
there is a need to change the scope of the positive list. In April
2002, 829 non-prescription alimentary tract drugs were removed
from the list of reimbursable drugs and made non-reimbursable
even when doctors prescribed them. This study investigated the
effect of delisting on the prescribing pattern of alimentary tract
drugs. METHODS: Health insurance reimbursement claims data
before (October 2001) and after (October 2002, October 2003)
the delisting were analyzed for 707 clinics (4% randomized sam-
pling). We calculated the prescription rate of alimentary tract
drugs and examined the use of alimentary tract drugs by dis-
eases. RESULTS: The prescription rate for alimentary tract drugs
declined from 79.03% in October 2001 to 59.91% in October
2002 and to 61.58% in October 2003. The prescription rate for
digestives, of which all products were delisted, dropped sharply
from 32.03% before delisting to 1.9% in October 2002 and to
0.75% in October 2003. Medicines for intestinal disorders were
prescribed less frequently after delisting, while the prescription
rate for anti-ulcerants and antacids increased by 3–4%. In
general, the drugs on the positive list were not switched to
delisted drugs, even though some listed ingredients were used
more often. Also, the use of alimentary tract drugs for patients
who had respiratory diseases such as common cold reduced more
than by 20% after delisting, while the prescription rate for those
with gastric ulcer decreased by 1% after delisting. CONCLU-
SIONS: The delisting policy reduced the use of alimentary tract
drugs. But there was difference in the effect of  delisting by drug
classiﬁcation and some delisted drugs were found to be switched
to listed drugs. The use of alimentary tract drugs changed less
for diseases for which they are essential than for supplementary 
purposes.
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OBJECTIVES: The Dutch Ministry of Health (MoH) has
requested the Health Care Insurance Board (CVZ) to advise on
the modernisation of the drug reimbursement system
(Geneesmiddelenvergoedingssysteem GVS). On behalf of the
CVZ, PharMerit assessed the impact of market competition on
pricing and reimbursement (P&R) of patented drugs in Belgium,
France and Germany. METHODS: In-depth interviews with
reimbursement policy-makers; analysis of laws and policy docu-
ments. Impact of market competition (deﬁned as total number
of marketed generics and therapeutically comparable patented
drugs) on drug reimbursement decision-making was assessed in
each of the study countries. RESULTS: In Belgium and France,
drug P&R is determined in negotiation between manufacturers
and authorities. Generic prices are set 30–40% lower than spe-
cialties. “Late-arrivals” (e.g. me-too’s or other therapeutically
comparable patented drugs) receive lower prices than (ﬁrst-in-
class) “early-arrivals”. Since 2004, patented drugs in Germany
are no longer excluded from therapeutic reference-pricing if at
least 3 comparable alternatives are available. Sickness Funds are
legally entitled to adjust cluster reference prices in case justiﬁed
by “changes in the market”. Cluster reference prices with a high
number of generics (off-patent and patented drugs) are expected
to be reduced in the future. Prices of patented late-arrivals in The
Netherlands are not directly subject to market competition con-
siderations and tend to level the cluster reference price, based 
on the average price of clustered products. Recently, prices of
generics have been lowered in an informal agreement between
MoH and manufacturers. The MoH is seeking ways to mod-
ernise the reimbursement system. CONCLUSIONS: In Belgium
and France, late-arriving patented drugs can be assigned rela-
tively lower prices in comparison to their early-arriving com-
petitors. In Germany, introduction of late-arrivals may impact
on P&R of both early and late-arrivals. In the current set-up of
the Dutch GVS, market introduction of late-arrivals does not
impact on cluster reference prices.
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OBJECTIVES: Reimbursement policies clearly affect the ratio-
nal use of drugs. In Turkey there are three state funded social
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security and several private insurance agencies. The regulatory
and functional differences between those agencies make drug
reimbursement regulations complicated for the health care pro-
fessionals and patients. Turkish Society of Clinical Pharmacol-
ogy organized a three-day meeting with all stakeholders
(parliamentarians, academicians, Ministry of Health, Ministry of
Finance, State Planning Organization, international and local
drug industry representatives and social security institutions,
medical and pharmacist associations) for discussion of the
present reimbursement system and its future. METHODS: Dis-
cussion was performed in six steps. First, representatives of the
stakeholders presented their own policies and problems. Second,
a brainstorm was performed. All the ideas were recorded as a
consensus text in the third step. The next day, participants were
divided into four groups to evaluate the text at a round table dis-
cussion. Finally, collecting all the suggestions, the consensus text
was rewritten and distributed to the representatives after the
meeting to ask for their approval. RESULTS: All stake holders,
except multinational drug companies, were agreeing to use
national pharmacoeconomic data for reimbursement issues.
Other main outcomes of this consensus meeting accepted by all
the representatives were as follows: All health care professionals
should get enough education to establish the rational use of
drugs. An autarchic “National Drug Institution” should be built.
CONCLUSIONS: A “Reimbursement Commission” should be
built with the participation of all representatives and should
work for the standardization of reference drug prices. State
funded social insurance systems should be kept under one valid
insurance system. OTC drug deﬁnition and the OTC drug list
should be deﬁned clearly, and preventive therapy such as vacci-
nation should be reimbursed in full.
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OBJECTIVES: Comparative analysis and productivity measure-
ment of outpatient care, provided and reimbursed by IKA, the
largest National Social Insurance Institution in Greece. In-house
services of Patission Local Health Unit (LHU)) are compared to
Family Doctor’s private surgeries’ medical visits (out-sourcing
services). METHODS: A prospective study of medical visits for
a 6 month period (September 1, 2002 to February 28, 2003).
Sample consisted of 23,982 outpatient visits to 3 specialities (5
Cardiologists with 12,538 visits, 3 Surgeons with 4544 visits and
3 Otolaryngologists with 6900 visits) offering their services in a
LHU and 3 family doctors with 17,295 visits, belonging to the
same LHU but offering their services in their private surgeries
with 2942, 8245, and 6105 visits respectively. Clinical and eco-
nomic data is derived from IKA’s Central Administration, its
Information System, from LHU and interviews with executives.
RESULTS: Productivity among all doctors presented signiﬁcant
divergences. The productivity of family doctors in their private
surgeries was higher than LHU’s doctors while the average
waiting time appeared to be higher for medical visits to LHU’s
doctors. Average cost of medical visits to the LHU was estimated
at 8.48€ while cost per speciality was 7.19€ for the cardiologist,
10.43€ for the surgeon and 7.83€ for the otolaryngologist.
Average cost per visit to family doctors was 2.33€, while cost per
specialty was 3.69€, 1.53€ and 1.77€ respectively. CONCLU-
SIONS: Average cost of medical visit to family doctor’s private
surgery was lower than the cost of medical visit to LHU’s. The
provision of outpatient medical care offered by IKA through out-
sourcing seems to be most cost-effective. Economic evaluation
studies, combining the efﬁcient use of health resources with the
adoption of effective patterns of patients’ management, should
be conducted at national level by all social funds and incorpo-
rated in their decision making process.
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OBJECTIVE: To examine the time of occurrence, type and cost
of injuries resulting from bicycle accidents treated in Emergency
Departments (ED). METHODS: Cases were identiﬁed from
2002 ED and hospital databases from Massachusetts using ICD-
9 diagnosis and E-codes (E826.0–E826.9). Hospital cases were
limited to those admitted via the ED. Cost estimates include facil-
ity, accommodations and ancillary services, reported in 2002
US$. Charges were adjusted using a 0.61 cost-to-charge ratio.
RESULTS: Of 10,025 bicycle accident cases identiﬁed, 75% were
male. Mean age was 28 years (median: 15, range: <1–98), 61%
were under 20 years. Transport by ambulance was used for 13%
of those injured; <1% by helicopter. The cyclist was the injured
party in 96% of cases; a pedestrian or other person in 4%.
Almost half (48%) arrived between 4:00 and 9:00 PM, 36% on
a weekend and 70% during May–September. The majority
(94%) were treated and released from ED, 2% died in ED, 3%
were admitted to hospital; and 1% were either transferred to
another facility, or left AMA. Highest admission rate (12%) 
was seen in older patients (60+ years). Skull fractures and other
head injuries accounted for 6% of cases. Other fractures, dis-
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